Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.

Bibliographic Details
Title:	Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice.
Authors:	Byong H Kang, Noor Momin, Kelly D Moynihan, Murillo Silva, Yingzhong Li, Darrell J Irvine, K Dane Wittrup
Source:	PLoS ONE, Vol 16, Iss 4, p e0248903 (2021)
Publisher Information:	Public Library of Science (PLoS), 2021.
Publication Year:	2021
Collection:	LCC:Medicine LCC:Science
Subject Terms:	Medicine, Science
More Details:	Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1932-6203
Relation:	https://doaj.org/toc/1932-6203
DOI:	10.1371/journal.pone.0248903
Access URL:	https://doaj.org/article/71a03d82b9834e24a26869f51fafa8cd
Accession Number:	edsdoj.71a03d82b9834e24a26869f51fafa8cd
Database:	Directory of Open Access Journals
Full text is not displayed to guests.	Login for full access.

More Details
ISSN:	19326203
DOI:	10.1371/journal.pone.0248903
Published in:	PLoS ONE
Language:	English